M. Tobi et al., URINARY ORGAN-SPECIFIC NEOANTIGEN - A POTENTIALLY DIAGNOSTIC-TEST FORCOLORECTAL-CANCER, Digestive diseases and sciences, 40(7), 1995, pp. 1531-1537
Urinary organ-specific neoantigen from colorectal cancer patients has
been used to make a monoclonal antibody, BAC 18.1. In this study we as
sessed the potential of this antibody for the diagnosis of colorectal
cancer. We evaluated binding in both urine and effluent samples and co
mpared it with effluent carcinoembryonic antigen standardized for both
volume (nanograms per milliliter) and protein. Urinary organ-specific
antigen as detected by BAC 18.1 was significantly greater in 29 cance
r patients (A(405): 0.717 +/- 0.500) vs 27 controls [0.121 +/- 0.273 (
P < 0.05)]. Considerable overlap of binding of BAC 18.1 was observed i
n the colonic effluent of patients with CRC (N = 13), adenomas (N = 26
), inflammatory bowel disease (N = 8), or having a normal colonoscopic
examination (N = 24). CEA levels (nanograms per milliliter) were sign
ificantly elevated in the effluent samples of patients with a past his
tory of colorectal cancer, as compared to that of normal individuals (
P < 0.05). The presence of the Mr 30,000 organ-specific neoantigen in
colonic effluent was also demonstrated by western blot. Organ-specific
neoantigen originates in the colon and is excreted into the urine, so
the BAC 18.1 binding levels in the urine may be a diagnostic aid for
CRC.